Some Indirect Claims Stay In Aggrenox Pay-For-Delay Row

By Eric Kroh ( August 10, 2016, 2:37 PM EDT) -- A Connecticut federal judge on Tuesday kept alive some antitrust claims by Humana Inc., employee health funds and other indirect purchasers of blood-clot medication Aggrenox in multidistrict litigation that accuses Teva Pharmaceuticals USA Inc. and Boehringer Ingelheim Pharmaceuticals Inc. of paying to keep generics off the market....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!